GREY:VIVXF - Post by User
Comment by
StoneMan45on Nov 13, 2021 8:21am
128 Views
Post# 34122784
RE:from Oct
RE:from Oct Conclusion The landmark deal announced with AB Vista could be a “game changer” for the company as Avivagen now has a global partner that gives immediate credibility to the OxC-beta technology. We believe management made the right move by limiting the deal with AB Vista to only a select few jurisdictions instead of going for a global deal. Once sales begin to ramp up, we believe it will be just a matter of time before interest in acquiring the company outright begins to increase, and by that time we are confident that the share price will more accurately reflect the company’s true value. Our valuation remains at $3.50.